SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children.
Ontology highlight
ABSTRACT: Although children have been largely spared from coronavirus disease 2019 (COVID-19), the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility, combined with fluctuating mask mandates and school reopenings, has led to increased infections and disease among children. Thus, there is an urgent need to roll out COVID-19 vaccines to children of all ages. However, whether children respond equivalently to adults to mRNA vaccines and whether dosing will elicit optimal immunity remain unclear. Here, we aimed to deeply profile the vaccine-induced humoral immune response in 6- to 11-year-old children receiving either a pediatric (50 μg) or adult (100 μg) dose of the mRNA-1273 vaccine and to compare these responses to vacci
SUBMITTER: Bartsch YC
PROVIDER: S-EPMC9348753 | biostudies-literature | 2022 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA